MIRA Pharmaceuticals (MIRA) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MIRA Pharmaceuticals (MIRA) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 44.4% versus a loss of 88.4%. TransCode Therapeutics is the larger company by market cap ($31.5 million vs $31.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRA | RNAZ |
|---|---|---|
| Share price | $0.7455 | $1.86 |
| Market cap | $31.33M | $31.49M |
| 1-day change | +6.05% | +8.77% |
| YTD return | -50.63% | -74.96% |
| 1-year return | -44.37% | -88.45% |
| 5-year return | — | -100.00% |
| EPS (TTM) | $-1.21 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.45 | $15.94 |
| 52-week low | $0.60 | $1.52 |
| Distance from 52-week high | -69.57% | -88.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +369.48% | — |
| Average volume | 585.75K | 50.19K |
| Shares outstanding | 42.02M | 16.93M |
| Employees | — | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIRA has outperformed RNAZ by 44.1 percentage points over the past year.
About MIRA Pharmaceuticals
MIRA stock →MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
Health Care · Biotechnology: Pharmaceutical Preparations
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
MIRA vs RNAZ FAQ
Which is bigger, MIRA Pharmaceuticals or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $31.49M compared with $31.33M for MIRA Pharmaceuticals (MIRA).
Which stock has performed better over the past year, MIRA or RNAZ?
MIRA returned -44.37% over the past 12 months, compared with -88.45% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are MIRA Pharmaceuticals and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.